Table 4.
Detailed matters about chemotherapy
| Characteristic | Value |
|---|---|
| Type of first line chemotherapy | |
| Platinum-based doublet | 9 (75) |
| TKI | 2 (16.7) |
| Docetaxel | 1 (8.3) |
| Response to chemotherapya | |
| Complete response | 0 |
| Partial response | 3 (25) |
| Stable disease | 4 (33.3) |
| Progressive disease | 2 (16.7) |
| Assessment not available | 3 (25) |
| Progression-free survival, monb | 2.8 (1.2–4.5) |
Values are presented as number (%) or median (95% confidence interval).
TKI, tyrosine kinase inhibitor.
a
Assessment of response followed Response Evaluation Criteria in Solid Tumors (RECIST).
b
Progression-free survival was calculated for nine patients.